Clostridial spores to treat solid tumours - Potential for a new therapeutic modality

Current Gene Therapy

Volumn 10, Issue 1, 2010, Pages 15-26

  Mengesha, Asferd ^a   Wei, Jou Z ^a   Zhou, Shu Feng ^b   Wei, Ming Q ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b RMIT UNIVERSITY   (Australia)

Author keywords

Clostridial spores; ClosTron; Hypoxia; Necrosis; Oncolysis; Tumour therapy

Indexed keywords

BACTERIAL VECTOR; DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; BACTERIAL SPORE; CANCER THERAPY; CLOSTRIDIA; CODON; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; HUMAN; HYPOXIA; IMMUNITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; SOLID TUMOR; TUMOR CELL DESTRUCTION;

ANTINEOPLASTIC AGENTS; CLOSTRIDIUM; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; NEOPLASMS; SPORES, BACTERIAL;

CLOSTRIDIA;

EID: 77950823901     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Thews O, Wolloscheck T, Dillenburg W, et al. Microenvironmen- tal adaptation of experimental tumours to chronic vs acute hypoxia. Br J Cancer 2004; 91(6): 1181-1189
2. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991; 51(12): 3316-3322
3. Nordsmark M, Loncaster J, Aquino-Parsons C, et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 2003; 67(1): 35-44.
4. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26(2): 225-239
5. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3(2): 65-71.
6. Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002; 38(2): 240-257
7. Wouters BG, Koritzinsky M, Chiu RK, Theys J, Buijsen J, Lambin P. Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol 2003; 13(1): 31-41.
8. Nordsmark M, Loncaster J, Aquino-Parsons C, et al. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol 2006; 80(2): 123-131
9. Janssen HL, Haustermans KM, Balm AJ, Begg AC. Hypoxia in head and neck cancer: how much, how important? Head Neck 2005; 27(7): 622-638
10. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59(18): 4525-4528
11. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379(6560): 88-91.
12. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381: 335-354
13. Lambin P, Theys J, Landuyt W, et al. Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe 1998; 4(4): 183-188
14. Lemmon MJ, van Zijl P, Fox ME, et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvi- ronment. Gene Ther 1997; 4(8): 791-796
15. Minton NP. Clostridia in cancer therapy. Nat Rev Microbiol 2003;1(3): 237-242
16. Theys J, Landuyt AW, Nuyts S, Van Mellaert L, Lambin P, Anne J. Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect Prev 2001; 25(6): 548-557
17. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001; 98(26): 15155-15160
18. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002; 9(4): 291-296
19. Li Z, Fallon J, Mandeli J, Wetmur J, Woo SL. A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst 2008; 100(19): 1389-1400
20. Mengesha A, Dubois L, Chiu RK, et al. Potential and limitations of bacterial-mediated cancer therapy. Front Biosci 2007; 12: 3880-3891
21. Moese JR, Moese G. Oncolysis by Clostridia. I: activity of clostridium butyricum (M-55) and other nonpathogenic clostridia against the ehrlich carcinoma. Cancer Res 1964; 24: 212-216
22. Mose JR, Mose G, Propst A, Heppner F. Oncolysis of malignant tumors through the M 55 clostridium strain. II: Med Klin 1967; 62(6): 220-225
23. Schmidt W, Fabricius EM, Schneeweiss U. The tumour- Clostridium phenomenon: 50 years of developmental research (Review). Int J Oncol 2006; 29(6): 1479-1492
24. Engelbart K, Gericke D. Oncolysis by Clostridia. V: transplanted Tumors of the hamster. Cancer Res 1964; 24: 239-242
25. Thiele EH, Arison RN, Boxer GE. Oncolysis by Clostridia. Iv: effect of nonpathogenic clostridial spores in normal and pathological tissues. Cancer Res 1964; 24: 234-238
26. Thiele EH, Arison RN, Boxer GE. Oncolysis by Clostridia. Iii: effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res 1964; 24: 222-233
27. Heppner F, Mose JR. The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir (Wien) 1978; 42(1-2): 123-125
28. Heppner F, Mose JR. Oncolysis of malignant gliomas through apathogenic clostridia (strain "M 55"). Zentralbl Neurochir 1966;27(4):183-192
29. Minton NP, Mauchline ML, Lemmon MJ, et al. Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol Rev 1995; 17(3): 357-364
30. Wei MQ, Mengesha A, Good D, Anne J. Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 2008; 259(1): 16-27.
31. Theys J, Pennington O, Dubois L, et al. Repeated cycles of Clos-tridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 2006; 95(9): 1212-1219
32. Bettegowda C, Dang LH, Abrams R, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci USA 2003; 100(25): 15083-15088
33. Cheong I, Huang X, Bettegowda C, et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006; 314(5803): 1308-1311
34. Theys J, Barbe S, Landuyt W, et al. Tumor-specific gene delivery using genetically engineered bacteria. Curr Gene Ther 2003; 3(3):207-221
35. Diaz LA, Jr, Cheong I, Foss CA, et al. Pharmacologic and toxi- cologic evaluation of C. novyi-NT spores. Toxicol Sci 2005; 88(2):562-575
36. Landuyt W, Verdoes O, Darius DO, et al. Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyo-sarcomas. Eur J Cancer 2000; 36(14): 1833-1843.
37. Theys J, Landuyt W, Nuyts S, et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 2001; 8(4): 294-297
38. Barbe S, Van Mellaert L, Theys J, et al. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett 2005; 246(1): 67-73.
39. Liu SC, Ahn GO, Kioi M, Dorie MJ, Patterson AV, Brown JM. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR- 104. Cancer Res 2008; 68(19): 7995-8003.
40. Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009; 14(11): 4517-4545
41. Both GW. Gene-directed enzyme prodrug therapy for cancer: a glimpse into the future. Discov Med 2009; 8(42): 97-103.
42. Both GW. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther 2009;11(4): 421-432
43. Schepelmann S, Springer CJ. Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 2006; 6(6): 647-670
44. Fox ME, Lemmon MJ, Mauchline ML, et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther 1996; 3(2): 173-178
45. Theys J, Nuyts S, Landuyt W, et al. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. Appl Environ Microbiol 1999; 65(10):4295-4300
46. Shinohara ET, Maity A. Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment. Curr Mol Med 2009; 9(9): 1034-1045
47. Theys J, Landuyt W, Nuyts S, et al. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol 2001; 30(1): 37-41.
48. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3(11): 999-1005.
49. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21(2):137-148
50. Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002; 12(1): 33-42.
51. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosur-veillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6(10): 715-727
52. Zerbini A, Pilli M, Penna A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006; 66(2): 1139-1146
53. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13(1): 54-61. (Pubitemid 46067386)
54. den Brok MH, Sutmuller RP, van der Voort R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64(11): 4024-4029
55. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10(1): 48-54.
56. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006; 27(1): 49-55.
57. Avogadri F, Martinoli C, Petrovska L, et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res 2005; 65(9): 3920-3927
58. Avogadri F, Mittal D, Saccheri F, et al. Intra-tumoral Salmonella typhimurium induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease. Eur J Immunol 2008; 38(7): 1937-1947
59. Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA 2004; 101(42): 15172-15177
60. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116(8): 546-554
61. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127(1): 3-11.
62. Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol 2004; 22(7): 346-353
63. Zdanovsky AG, Zdanovskaia MV. Simple and efficient method for heterologous expression of clostridial proteins. Appl Environ Microbiol 2000; 66(8): 3166-3173
64. Makoff AJ, Oxer MD, Romanos MA, Fairweather NF, Ballantine S. Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons. Nucleic Acids Res 1989;17(24): 10191-10202
65. Lee SF, Li YJ, Halperin SA. Overcoming codon-usage bias in heterologous protein expression in Streptococcus gordonii. Microbiology 2009; 155(Pt 11): 3581-3588
66. Heap JT, Pennington OJ, Cartman ST, Carter GP, Minton NP. The ClosTron: a universal gene knock-out system for the genus Clostridium. J Microbiol Methods 2007; 70(3): 452-464
67. Heap JT, Pennington OJ, Cartman ST, Minton NP. A modular system for Clostridium shuttle plasmids. J Microbiol Methods 2009; 78(1): 79-85.
68. Heap JT, Kuehne SA, Ehsaan M, et al. The ClosTron: Mutagenesis in Clostridium refined and streamlined. J Microbiol Methods 2010; 80(1): 45-50.